

## Summary of related Endostatin studies:

Mouse/rat studies	Human studies
<p><b><u><a href="#">Endostatin expression in the murine model of ischaemia/reperfusion-induced acute renal failure.</a></u></b>  <i>Bellini MH et al., Nephrology 2007;12(5):459–465.</i></p> <p>“These data suggest the local synthesis of a 30 kDa endostatin-related fragment following acute renal failure and suggest its role in the modulation of renal capillary density.”</p>	<p><b><u><a href="#">Plasma endostatin may improve acute kidney injury risk prediction in critically ill patients.</a></u></b>  <i>Mårtensson J et al., 2016 Ann Intensive Care; 6:6.</i></p> <p>“In this cohort of critically ill patients, plasma endostatin improved AKI prediction based on clinical risk factors, while cystatin C and NGAL did not.”</p>
<p><b><u><a href="#">Endostatin and kidney fibrosis in aging: a case for antagonistic pleiotropy?</a></u></b>  <i>Lin CHS et al., Am J Physiol Heart Circ Physiol 2014;306:H1692–H1699.</i></p> <p>“In conclusion, the findings are consistent with the hypothesis on elevation of endostatin levels and parallel microvascular rarefaction and induction of renal fibrosis in aging mice.”</p>	<p><b><u><a href="#">The association between endostatin and kidney disease and mortality in patients with type 2 diabetes.</a></u></b>  <i>Carlsson AC et al., Diabetes &amp; Metabolism 2016;42(5): 351–357.</i></p> <p>“In patients with T2D, circulating endostatin levels can predict the progression of kidney disease and mortality independently of established kidney disease markers. The clinical usefulness of endostatin as a risk marker in such patients merits further studies.”</p>
<p><b><u><a href="#">Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.</a></u></b>  <i>Ichinose K et al., Diabetes 2005;54: 2891–2903.</i></p> <p>“These results demonstrate the potential use of antiangiogenic endostatin peptide as a novel therapeutic agent in diabetic nephropathy.”</p>	<p><b><u><a href="#">Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival.</a></u></b>  <i>Kanbay et al., Eur J Intern Med 2016;33:81–87.</i></p> <p>“Endostatin levels are independently associated with incident CVE in CKD patients, but show limited prediction abilities for all-cause mortality and CVE above traditional and renal-specific risk factors.”</p>
<p><b><u><a href="#">Endostatin improves cancer-associated systemic syndrome in a lung cancer model.</a></u></b>  <i>Wang X et al., Oncol Lett 2015; (5): 2023–2030.</i></p> <p>“Collectively, these findings indicate that endostatin improves CASS in tumor-bearing mice by decreasing the serum levels of VEGF and IL-6.”</p>	<p><b><u><a href="#">Endostatin level is associated with kidney injury in the elderly: findings from two community-based cohorts.</a></u></b>  <i>Ruge et al., Am J Nephrol. 2014;40(5):417–424.</i></p> <p>“Higher circulating endostatin is associated with lower GFR and higher albuminuria and independently predicts incident CKD in elderly subjects. Further studies are warranted to investigate the underlying mechanisms linking endostatin to kidney pathology, and to evaluate the clinical relevance of our findings.”</p>